NCT07354295Recruiting
Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus）
Multimodal AI-based Therapy Response Prediction and Risk Stratification for Esophageal Cancer
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
This AI-driven model leverages multimodal data-such as radiomics, pathomics, genomics, and broader multi-omics profiles-to capture complementary aspects of tumor biology and predict treatment response and prognosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 26 Jul 2025
- Primary completion date
- 30 Sept 2030
- Lead sponsor
- Shu Peng
- NCT number
- NCT07354295
What you commit to
- Study type: Observational
- Planned participants: 1500
- From 26 Jul 2025 to the primary completion date, 30 Sept 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of another primary malignant tumor
- Severe systemic disease
Other
- Imaging data quality insufficient for analysis
Who the study is looking for
- Histopathologically diagnosed esophageal cancer
- Complete baseline clinical data available (including demographic characteristics, ECOG performance score, TNM staging, etc.)
- No other primary malignant tumors
- Provision of informed consent
- Availability of pre-treatment CT imaging
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.